Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects
Technical Report,01 Aug 2017,31 Aug 2018
University of Florida Gainesville United States
Pagination or Media Count:
The overall objective is to provide proof-of-principle that recombinant human relaxin rhRLX administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesisvasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the third study conducted during this reporting period demonstrated reproducible implementation of uniform cranial lesions of 3.0 mm diameter and circulating concentrations of relaxin of 4.9 1.3 ngml ngml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice 70 each. Consistent with this finding is that there were also no significant differences in bone volume, bonetissue volume or bone and tissues mineralization densities gcm3. Ina parallel study, we applied relaxin locally in collagen scaffolding 1.0 gscaffold however, again, the lesion closure was comparable in the relaxin- and vehicle-treated mice 80 each. Consistent with this finding again is that there were also no significant differences in bone volume, bonetissue volume or bone and tissues mineralization densities gcm3. In these 2protocols we also utilized older mice of 13-14 months of age, the idea being that the relative impairment of bone healing dueto age may be more amenable to improvement by relaxin.
- Anatomy and Physiology